$CAPR
CAPRICOR THERAPEUTICS, INC. Stock $capr

$capr Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000114420418059980 Filed on November 14, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q3
Revenue	$650.0K	$219.2K	$313.3K
YoY Change	35.42%	-30.01%	-58.05%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.100M	$1.260M	$1.090M
YoY Change	-11.29%	15.6%	-13.49%
% of Gross Profit
Research & Development	$2.850M	$3.132M	$1.862M
YoY Change	13.1%	68.17%	-60.6%
% of Gross Profit
Depreciation & Amortization	$50.00K	$40.00K	$30.00K
YoY Change	66.67%	33.33%	50.0%
% of Gross Profit
Operating Expenses	$3.950M	$4.391M	$2.951M
YoY Change	5.33%	48.8%	-50.71%
Operating Profit		-$4.172M	-$2.638M
YoY Change		58.16%	-49.66%
Interest Expense	$50.00K	$0.00	$107.7K
YoY Change	-171.43%	-100.0%	9.02%
% of Operating Profit
Other Income/Expense, Net		$35.79K	-$97.26K
YoY Change		-136.8%	4.2%
Pretax Income	-$3.260M	-$4.140M	-$2.730M
YoY Change	-126.48%	51.65%	-48.78%
Income Tax
% Of Pretax Income
Net Earnings	-$3.260M	-$4.136M	-$2.735M
YoY Change	-126.48%	51.23%	-48.72%
Net Earnings / Revenue	-501.54%	-1886.52%	-873.04%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.048M	-$1.353M	-$1.167M
COMMON SHARES
Basic Shares Outstanding	31.07M shares	30.75M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.256M	$10.37M	$13.89M
YoY Change	-48.63%	-25.35%	-32.29%
Cash & Equivalents	$4.259M	$4.378M	$8.897M
Short-Term Investments	$2.997M	$5.994M	$4.998M
Other Short-Term Assets	$1.010M	$850.0K	$800.0K
YoY Change	-18.55%	6.25%	11.11%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$8.471M	$11.39M	$15.23M
YoY Change	-46.09%	-25.2%	-32.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$574.2K	$622.3K	$390.0K
YoY Change	54.32%	59.56%	10.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$150.0K	$160.0K	$60.00K
YoY Change	50.0%	166.67%	0.0%
Total Long-Term Assets	$775.8K	$840.2K	$560.0K
YoY Change	38.25%	50.03%	-72.91%
TOTAL ASSETS
Total Short-Term Assets	$8.471M	$11.39M	$15.23M
Total Long-Term Assets	$775.8K	$840.2K	$560.0K
Total Assets	$9.247M	$12.23M	$15.79M
YoY Change	-43.18%	-22.53%	-35.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.260M	$1.880M	$1.360M
YoY Change	-24.55%	38.24%	-70.56%
Accrued Expenses			$1.170M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$14.16M
YoY Change		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.255M	$1.876M	$16.69M
YoY Change	-24.87%	-88.76%	150.21%
LONG-TERM LIABILITIES
Long-Term Debt	$3.380M	$3.380M	$3.380M
YoY Change	0.0%	0.0%	-80.13%
Other Long-Term Liabilities			$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$3.376M	$3.376M	$3.380M
YoY Change	0.0%	-0.11%	-80.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.255M	$1.876M	$16.69M
Total Long-Term Liabilities	$3.376M	$3.376M	$3.380M
Total Liabilities	$4.631M	$5.252M	$20.06M
YoY Change	-8.23%	-73.82%	-17.86%
SHAREHOLDERS EQUITY
Retained Earnings	-$66.74M	-$63.48M
YoY Change	29.47%
Common Stock	$71.34M	$70.44M
YoY Change	13.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.616M	$6.980M	-$4.270M
YoY Change
Total Liabilities & Shareholders Equity	$9.247M	$12.23M	$15.79M
YoY Change	-43.18%	-22.53%	-35.48%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	-$3.260M	-$4.136M	-$2.735M
YoY Change	-126.48%	51.23%	-48.72%
Depreciation, Depletion And Amortization	$50.00K	$40.00K	$30.00K
YoY Change	66.67%	33.33%	50.0%
Cash From Operating Activities	-$3.770M	-$2.980M	-$3.190M
YoY Change	41.2%	-6.58%	66.15%
INVESTING ACTIVITIES
Capital Expenditures	$10.00K	-$140.0K	-$10.00K
YoY Change		1300.0%	0.0%
Acquisitions
YoY Change
Other Investing Activities	$2.990M	$0.00	-$1.000M
YoY Change	-200.0%	-100.0%
Cash From Investing Activities	$3.000M	-$140.0K	-$1.010M
YoY Change	-200.33%	-86.14%	4950.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	510.0K	1.050M	4.620M
YoY Change	-83.17%	-77.27%	-60.51%
NET CHANGE
Cash From Operating Activities	-3.770M	-2.980M	-3.190M
Cash From Investing Activities	3.000M	-140.0K	-1.010M
Cash From Financing Activities	510.0K	1.050M	4.620M
Net Change In Cash	-260.0K	-2.070M	420.0K
YoY Change	-90.11%	-592.86%	-95.7%
FREE CASH FLOW
Cash From Operating Activities	-$3.770M	-$2.980M	-$3.190M
Capital Expenditures	$10.00K	-$140.0K	-$10.00K
Free Cash Flow	-$3.780M	-$2.840M	-$3.180M
YoY Change	41.57%	-10.69%	66.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1496251	USD
CY2018Q3	capr	Accounts Payable And Accrued Expenses Related Party Current AccountsPayableAndAccruedExpensesRelatedPartyCurrent	132347	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	CAPRICOR THERAPEUTICS, INC.
	dei	Entity Central Index Key EntityCentralIndexKey	0001133869
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Trading Symbol TradingSymbol	CAPR
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	31067359	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6140135	USD
CY2018Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	5994120	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	7984800	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	742002	USD
CY2018Q3	us-gaap	Grants Receivable Current GrantsReceivableCurrent	172589	USD
CY2017Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	344575	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	426422	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	501164	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	11392646	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	15712676	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	60591	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	93048	USD
CY2018Q3	us-gaap	Other Assets OtherAssets	157302	USD
CY2017Q4	us-gaap	Other Assets OtherAssets	95969	USD
CY2018Q3	us-gaap	Assets Assets	12232816	USD
CY2017Q4	us-gaap	Assets Assets	16273789	USD
CY2018Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1743788	USD
CY2017Q4	capr	Accounts Payable And Accrued Expenses Related Party Current AccountsPayableAndAccruedExpensesRelatedPartyCurrent	174424	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1876135	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1670675	USD
CY2018Q3	us-gaap	Other Long Term Debt OtherLongTermDebt	3376259	USD
CY2017Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	3376259	USD
CY2018Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3376259	USD
CY2017Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3376259	USD
CY2018Q3	us-gaap	Liabilities Liabilities	5252394	USD
CY2017Q4	us-gaap	Liabilities Liabilities	5046934	USD
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	30749	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	26271	USD
CY2018Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	70408501	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	62736783	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	20207	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	11620	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-63479035	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	107653	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-51547819	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12232816	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16273789	USD
CY2018Q3	capr	Collaboration Revenue CollaborationRevenue	0	USD
CY2017Q3	capr	Collaboration Revenue CollaborationRevenue	0	USD
	capr	Collaboration Revenue CollaborationRevenue	0	USD
	capr	Collaboration Revenue CollaborationRevenue	1367186	USD
CY2018Q3	us-gaap	Revenues Revenues	219247	USD
CY2017Q3	us-gaap	Revenues Revenues	313271	USD
	us-gaap	Revenues Revenues	1023274	USD
	us-gaap	Revenues Revenues	2190541	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3131999	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1862369	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9217423	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8247700	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1259180	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1088635	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3826972	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3524815	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	4391179	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	2951004	USD
	us-gaap	Operating Expenses OperatingExpenses	13044395	USD
	us-gaap	Operating Expenses OperatingExpenses	11772515	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4171932	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2637733	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12021121	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9581974	USD
CY2018Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	35792	USD
CY2017Q3	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	10393	USD
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	89905	USD
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	26726	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	318500	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	35792	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-97260	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	89905	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-291774	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-4136140	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-2734993	USD
CY2018Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1922	USD
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1276	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5069	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4134218	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2733717	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11922629	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9868679	USD
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	30610064	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23378141	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28862665	shares
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1367186	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22311369	shares
CY2018Q3	capr	Other Revenue OtherRevenue	46658	USD
CY2017Q3	capr	Other Revenue OtherRevenue	52500	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10091225	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11563582	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	15000733	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	11002271	USD
	capr	Other Revenue OtherRevenue	256633	USD
	capr	Other Revenue OtherRevenue	52500	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	11226855	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6202277	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1334779	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	8587	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	139140	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	6980422	USD
	us-gaap	Net Income Loss NetIncomeLoss	-11931216	USD
	us-gaap	Net Income Loss NetIncomeLoss	-9873748	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	114357	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	109595	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1334779	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1297362	USD
	capr	Increase Decrease From Grants Receivable IncreaseDecreaseFromGrantsReceivable	-171986	USD
	capr	Increase Decrease From Grants Receivable IncreaseDecreaseFromGrantsReceivable	37436	USD
	capr	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-74742	USD
	capr	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-152614	USD
	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	61333	USD
	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	-30	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	247537	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-1773999	USD
	capr	Increase Decrease In Accounts Payable And Accrued Expenses Related Party IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParty	-42077	USD
	capr	Increase Decrease In Accounts Payable And Accrued Expenses Related Party IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParty	-389314	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	318500	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	17000000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	19000000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	332081	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	32185	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1667186	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	7965544	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6202277	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8303697	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6341417	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8553697	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2082622	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	4955659	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6882137	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4551603	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	250000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	139140	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2018Q3	capr	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	10400000	USD
CY2017Q4	capr	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	14100000	USD
CY2018Q3	capr	Amount Available Under Grant Awards AmountAvailableUnderGrantAwards	4400000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4377797	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8897087	USD
CY2018Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	421718	USD
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	610175	USD
CY2018Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	400000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	700000	USD
CY2017Q4	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	15700000	USD
	us-gaap	Depreciation Depreciation	81900	USD
	us-gaap	Depreciation Depreciation	73034	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4799515	USD
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9507262	USD
CY2018Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1045827	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	713746	USD
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	423550	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	341650	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	622277	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	372096	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	32457	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	36562	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	10820	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	43276	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4330	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2165	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8368703	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8014863	shares
CY2018Q3	us-gaap	Marketable Securities MarketableSecurities	5994120	USD
CY2017Q4	us-gaap	Marketable Securities MarketableSecurities	7984800	USD
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1081716	shares
	capr	Class Of Warrant Or Right Granted ClassOfWarrantOrRightGranted	0	shares
	capr	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	0	shares
	capr	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	0	shares
CY2018Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1081716	shares
CY2017Q4	capr	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	4.01
	capr	Class Of Warrant Or Right Granted Weighted Average Exercise Price ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice	0
	capr	Class Of Warrant Or Right Exercised Weighted Average Exercise Price ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice	0
	capr	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	0
CY2018Q3	capr	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	4.01
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	12500	shares
CY2018Q2	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	29166	shares
CY2018Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	46250	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	16666	shares
CY2018Q2	capr	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Additional Grants In Period SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalGrantsInPeriod	4166	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.31
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.91
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.05
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1288530	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1297362	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	430433	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	427482	USD
CY2018Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	10500000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	521678	USD
CY2016Q4	capr	Disbursement Amount Under Grant Award DisbursementAmountUnderGrantAward	3100000	USD
CY2017Q4	capr	Disbursement Amount Under Grant Award DisbursementAmountUnderGrantAward	300000	USD
CY2018Q1	us-gaap	Operating Leases Rent Expense Minimum Rentals OperatingLeasesRentExpenseMinimumRentals	4190	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	133884	USD
	capr	Written Notice Period WrittenNoticePeriod	P90D
CY2016Q3	capr	Upfront Payment UpfrontPayment	2500	USD
CY2017Q4	capr	Reimbursed Expenses To Be Paid ReimbursedExpensesToBePaid	50000	USD
	capr	Payments For Reimbursement For Research And Development Expenses Incurred Related Party PaymentsForReimbursementForResearchAndDevelopmentExpensesIncurredRelatedParty	570000	USD
	capr	Payments For Reimbursement For Research And Development Expenses Incurred Related Party PaymentsForReimbursementForResearchAndDevelopmentExpensesIncurredRelatedParty	1002000	USD
CY2018Q3	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	47000	USD
	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	257000	USD
	capr	Compensation Receivable In Connection To Services To Be Provided CompensationReceivableInConnectionToServicesToBeProvided	2100000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	199091	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	166634	USD
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30748872	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26270491	shares
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30748872	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26270491	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;">Use of Estimates</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-left: 0.25in; margin-top: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'times new roman', 'serif';font-size: 10pt;margin-bottom: 0;margin-top: 0;text-align: justify;text-indent: 0.50in;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The most sensitive estimates relate to the recoverability and fair value of intangible assets and the assumptions used to estimate stock-based compensation expense. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017	capr	Loan Payable Forgiven LoanPayableForgiven	15700000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	107653	USD
	us-gaap	Interest Expense InterestExpense	318500	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2017Q3	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	52500	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	138292	USD
CY2018Q3	capr	Leases Monthly Payments For Additional Twelve Months LeasesMonthlyPaymentsForAdditionalTwelveMonths	19756	USD
	us-gaap	Payments For Royalties PaymentsForRoyalties	20000	EUR
	us-gaap	Related Party Transaction Other Revenues From Transactions With Related Party RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty	52500	USD
CY2018Q3	capr	Grant Income GrantIncome	172589	USD
CY2017Q3	capr	Grant Income GrantIncome	260771	USD
	capr	Grant Income GrantIncome	766641	USD
	capr	Grant Income GrantIncome	770855	USD
CY2018Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8368703	shares
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8014863	shares
CY2018Q3	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P1Y

Files In Submission

Name	View Source	Status
0001144204-18-059980-index-headers.html	Edgar Link	pending
0001144204-18-059980-index.html	Edgar Link	pending
0001144204-18-059980.txt	Edgar Link	pending
0001144204-18-059980-xbrl.zip	Edgar Link	pending
capr-20180930.xml	Edgar Link	completed
capr-20180930.xsd	Edgar Link	pending
capr-20180930_cal.xml	Edgar Link	unprocessable
capr-20180930_def.xml	Edgar Link	unprocessable
capr-20180930_lab.xml	Edgar Link	unprocessable
capr-20180930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv506373_10q.htm	Edgar Link	pending
tv506373_ex31-1.htm	Edgar Link	pending
tv506373_ex31-2.htm	Edgar Link	pending
tv506373_ex32-1.htm	Edgar Link	pending
tv506373_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CAPR
CAPRICOR THERAPEUTICS, INC. Stock $capr

2018 Q4 Form 10-Q Financial Statement

#000114420418059980 Filed on November 14, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CAPR CAPRICOR THERAPEUTICS, INC. Stock $capr

2018 Q4 Form 10-Q Financial Statement

#000114420418059980 Filed on November 14, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CAPR
CAPRICOR THERAPEUTICS, INC. Stock $capr